Literature DB >> 27365388

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Thomas F Patterson1, George R Thompson2, David W Denning3, Jay A Fishman4, Susan Hadley5, Raoul Herbrecht6, Dimitrios P Kontoyiannis7, Kieren A Marr8, Vicki A Morrison9, M Hong Nguyen10, Brahm H Segal11, William J Steinbach12, David A Stevens13, Thomas J Walsh14, John R Wingard15, Jo-Anne H Young16, John E Bennett17.   

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  allergic aspergillosis; amphotericin; aspergillosis; azoles; chronic aspergillosis; echniocandins; fungal diagnostics; invasive aspergillosis

Mesh：

Substances：

Year:  2016        PMID： 27365388      PMCID： PMC4967602          DOI： 10.1093/cid/ciw326

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  653 in total

1.  Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity.

Authors:  Jorien D'Haese; Koen Theunissen; Edith Vermeulen; Hélène Schoemans; Greet De Vlieger; Liesbet Lammertijn; Philippe Meersseman; Wouter Meersseman; Katrien Lagrou; Johan Maertens
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

Review 2.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

4.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

Authors:  Alexander Imhof; Dominik J Schaer; Urs Schanz; Urs Schwarz
Journal:  Swiss Med Wkly       Date:  2006-11-11       Impact factor: 2.193

5.  Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient.

Authors:  David P Lustenberger; Jaymes D Granata; Thomas J Scharschmidt
Journal:  Orthopedics       Date:  2011-11-09       Impact factor: 1.390

6.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

7.  Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.

Authors:  Jian Chen; Houmin Li; Ruoyu Li; Dingfang Bu; Zhe Wan
Journal:  J Antimicrob Chemother       Date:  2004-11-24       Impact factor: 5.790

8.  Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children.

Authors:  Veronique Dinand; Madasu Anjan; Jaswinder Kaur Oberoi; Shilpi Khanna; Satya Prakash Yadav; Chand Wattal; Anupam Sachdeva
Journal:  J Microbiol Immunol Infect       Date:  2014-02-28       Impact factor: 4.399

9.  A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation.

Authors:  A P Grigg; M Brown; A W Roberts; J Szer; M A Slavin
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

Review 10.  Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.

Authors:  Paul E Verweij; Susan J Howard; Willem J G Melchers; David W Denning
Journal:  Drug Resist Updat       Date:  2009-10-29       Impact factor: 18.500
View more
  550 in total

Review 1.  Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.

Authors:  Kaitlin Benedict; Malcolm Richardson; Snigdha Vallabhaneni; Brendan R Jackson; Tom Chiller
Journal:  Lancet Infect Dis       Date:  2017-07-31       Impact factor: 25.071

Review 2.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.

Authors:  Jacques F Meis; Anuradha Chowdhary; Johanna L Rhodes; Matthew C Fisher; Paul E Verweij
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

3.  Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.

Authors:  Xuemei Wu; Raman Venkataramanan; Ryan M Rivosecchi; Chenxiao Tang; Rachel V Marini; Ryan K Shields; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 4.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

5.  Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.

Authors:  Naveen Mangal; Issam S Hamadeh; Meghan J Arwood; Larisa H Cavallari; Tanay S Samant; Kenneth P Klinker; Jurgen Bulitta; Stephan Schmidt
Journal:  Clin Pharmacol Ther       Date:  2018-02-13       Impact factor: 6.875

Review 6.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

7.  The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies.

Authors:  Claudia Sassi; Marta Stanzani; Russell E Lewis; Giancarlo Facchini; Alberto Bazzocchi; Michele Cavo; Giuseppe Battista
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

Review 8.  Endoscopic ventriculo-cisterno-ventricular approach in the treatment of bilateral trapped temporal horn related to fungal infection in a child: case report and review of the literature.

Authors:  José Ascención Arenas-Ruiz; Horus Martinez-Maldonado; Vicente Gonzalez-Carranza; Samuel Torres-García; Fernando Chico-Ponce de Leon
Journal:  Childs Nerv Syst       Date:  2018-03-20       Impact factor: 1.475

9.  Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.

Authors:  Palash Samanta; Cornelius J Clancy; Rachel V Marini; Ryan M Rivosecchi; Erin K McCreary; Ryan K Shields; Bonnie A Falcione; Alex Viehman; Lauren Sacha; Eun Jeong Kwak; Fernanda P Silveira; Pablo G Sanchez; Matthew Morrell; Lloyd Clarke; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

10.  Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.

Authors:  Mahdi Abastabar; Nooshin Rahimi; Jacques F Meis; Narges Aslani; Sadegh Khodavaisy; Mojtaba Nabili; Ali Rezaei-Matehkolaei; Koichi Makimura; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.